Urine as a Specimen to Diagnose Infections in Twenty-First Century: Focus on Analytical Accuracy by Tamara Tuuminen
MINI REVIEW ARTICLE
published: 23 March 2012
doi: 10.3389/ﬁmmu.2012.00045
Urine as a specimen to diagnose infections in twenty-ﬁrst
century: focus on analytical accuracy
TamaraTuuminen1,2*
1 Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland
2 Mikkeli District Laboratory, Eastern Finland Laboratory Centre Joint Authority Enterprise, Mikkeli, Finland
Edited by:
Hao Shen, University of Pennsylvania
School of Medicine, USA
Reviewed by:
AdrianusWilhelmus Maria Van Der
Velden, Stony Brook University, State
University of NewYork, USA
Guoku Hu, Creighton University, USA
Shijun Zheng, China Agricultural
University, China
*Correspondence:
Tamara Tuuminen, Department of
Bacteriology and Immunology,
Haartman Institute, University of
Helsinki, P.O. Box 21, Helsinki 00014,
Finland.
e-mail: tamara.tuuminen@helsinki.ﬁ;
tamara.tuuminen@islab.ﬁ
Urine as a clinical specimen to diagnose infections has been used since ancient times.
Many rapid technologies to assist diagnosis of infections are currently in use. Alongside
traditional enzyme immunoassays (EIA), new technologies have emerged. Molecular analy-
sis of transrenal DNA to diagnose infections is also a rapidly growing ﬁeld. The majority
of EIAs utilize the detection of excreted sugar compounds of the outer microbial cell-wall
shed into the bloodstream and excreted into the urine.This mini-review focuses on current
knowledge on rapid urinary antigen detection tests to diagnose most common infections,
and highlights their diagnostic utility. The past and the future of urinalysis are also brieﬂy
discussed. The analysis of the literature shows that some methods are not quantitative,
and analytical sensitivity may remain suboptimal. In addition, the performance criteria and
technical documentation of some commercial tests are insufﬁcient. Clinical microbiologists
and physicians should be alert to assay limitations.
Keywords: urinalysis, urine, parasites, bacteria, viruses, fungi, immunochromatographic methods, ELISA
URINE AS A SPECIMEN
Milleniums ago urine as a diagnostic specimen attracted the
attention of early physicians. The history of uroscopy and uri-
nalysis starting from the time of Pharaonic Egypt has been
reviewed (White, 1991; Eknoyan, 2007). In Egypt and Aztec cul-
tures urine was used to disinfect wounds and was rubbed into the
skin to treat cuts and burns (Aztecs at Mixicoloro by Bernard
Ortiz de Montellano, Wayne State University, USA; Available
at: http://www.mexicolore.co.uk/index.php?one=azt&two=hea).
In medical papyri (1550 BCE) of ancient Egypt hematuria was
described using hieroglyphic symbols. This condition was most
probably caused by the worm Schistosoma haematobium (Papyrus,
1875) that plagued people living along the Nile Valley (Ruffer,
1910).
A Greek philosopher, naturalist, and the Roman emperor’s
physician, Claudius Galenos (129–200 CE) used the humoral
philosophy of ancient Greece which was based on the concept
of Hippocrates (460–370 BCE). According to Hellenistic teach-
ing the body is at equilibrium or homeostasis when four juices
are in balance. Urine was one of the four pillars of the galenic
humoral pathology. Centuries later this teaching was reintroduced
in Europe during the Renaissance.
Urine is an ideal clinical specimen for diagnostics because it is
excreted in large quantities and collection does not require inva-
sive methods. When conventional culture remains either negative
or unreliable, diagnosis of systemic infectious disease based on the
demonstration of bacterial antigens directly from urine has many
potential advantages. If the kidneys are intact, the excreted uri-
nary antigens have a lower MW than of albumin (<67 kDa) or for
transrenal DNA usually do not exceed 100 bp (Green et al., 2009).
This mini-review describes several methods for some
important infections, with the aim to illustrate their analytical
utility. Regarding the extent of the contemporary literature it
cannot be comprehensive.
URINE RAINBOW
Inspection of the color of urine is still useful today (Foot and
Fraser, 2006). Unusual color comprising practically the whole
spectrum of the rainbow is associated with various metabolic
or infectious diseases. Below are illustrated only a few examples
where the color of the urine is almost pathognomonic for a speciﬁc
infection.
RED COLOR, OR HEMATURIA
Hematuria is a condition of the presence of fresh blood in urine.
This symptom is found in a great variety of non-infectious dis-
orders but may also occur in relation to common infections, e.g.,
urinary tract infection (UTI). It may follow the prodromal period
(Katayama syndrome) after infection with Schistosoma haemato-
bium (CDC1, WHO: schistosomiasis2). Hematuria may also be
a symptom in viral zoonotic infections that may lead to hemor-
rhagic feverwith renal syndrome (HFRS).HFRS are caused by, e.g.,
Hantaan, Dobrava, Seoul viruses, or other arboviruses, e.g., Yel-
low Fever Disease, Rift Valley Fever, or tick-borne Crimea-Congo
Hemorrhagic Fever, or Dengue virus that may cause Hemorrhagic
Fever (DHF; WHO: Dengue3).
BROWN COLOR, OR BLACK WATER FEVER AND OTHER INFECTIONS
Black water fever is a urological manifestation of malaria caused
by Plasmodium falciparum. The color of urine turns brownish due
1www.cdc.gov/parasites/schistosomiasis/gen_info/faqs.html
2http://www.who.int/mediacentre/factsheets/fs115/en/index.html
3http://www.who.int/mediacentre/factsheets/fs117/en/
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to profuse hemoglobinuria. The brownish color of urine could be
observed also in cholestasis with jaundice that may occur, e.g., in
hepatitis A virus infection or in leptospirosis, a zoonotic disease,
caused by the spirochete Leptospira interrogans.
MILKY COLOR, OR CHYLURIA
Chyluria, or “milky urine”, is a symptom of the disturbance of
lymphatic ﬂow that may be caused by ﬁlariasis. A tapeworm,
Wuchereria bancrofti, accounts for 90% of human ﬁlariasis and
is widespread across tropic and subtropic areas (Kehinde et al.,
2008).
INFLAMMATORY MARKERS FROM URINE
A non-speciﬁc immune marker, neopterin, produced by human
macrophages has been detected from urine as well as blood. This
marker was found elevated in several inﬂammatory diseases and in
AIDS (Fuchs et al., 1989). Recently, pro-inﬂammatory chemokines
and cytokines have been studied in urine from patients with pul-
monary tuberculosis (TB). Only IP-10 was excreted in the urine
in measurable quantities exceeding those of patients without TB
(Cannas et al., 2010).
TESTS FOR HISTOPLASMOSIS
Progressive disseminated histoplasmosis (PDH) is common in
personswithAIDS, and other immunosuppressed patients (Kauff-
man, 2008). Antigen detection in plasma or urine is a signiﬁcant
adjunct to clinical and other diagnostic methods. The most fre-
quently reported test is the enzyme immunoassay (EIA) developed
by MiraVista Diagnostics (Indianapolis, IN, USA) which has been
recently reﬁned (Wheat et al., 2007). This method detects circu-
lating polysaccharides of Histoplasma capsulatum and provides
quantiﬁcation of antigen concentration. A quantitative assay that
can measure the polysaccharide down to 0.6 ng/ml (range 0.6–39)
was recently reported (Connolly et al., 2007). The manufacturer
of another commercially method, IMMY ALPHA (Immunol-
Mycologics, Inc., Norman, Oklahoma, USA), claims similar per-
formance although some authors reported controversy (McKinsey
et al., 2009).
Antigenuria is a sensitive laboratory biomarker of Histoplasma
clearance and was used to monitor the efﬁcacy of antimycotic
treatment (Hage et al., 2011a). On the other hand, positive urine
antigen levels may persist at low levels for months in patients
without clinical illness (Kauffman, 2008). In a large evaluation
in cases with acute pulmonary histoplasmosis (APH) the sen-
sitivity of both urine and blood detection methods was equal,
being positive in 64.6% (antigenuria) and 68.6% (antigenemia;
Swartzentruber et al., 2009). Combined, these tests reached a sensi-
tivity of 82.8%but, combinedwith the antibodydetectionmethod,
the sensitivity was 93.3% (Swartzentruber et al., 2009). In cul-
ture positive patients with PDH the sensitivity of the ELISA urine
method was higher but still suboptimal, 81%, but the speciﬁcity
in healthy persons and non-histoplasmosis disease reached 95%
(Scheel et al., 2009). In a multicenter evaluation the sensitivity of
antigen test was proportional to disease severity, 91.8% in PDH
and only 30.4% in subacute histoplasmosis (Hage et al., 2011b). It
was presumed that antigenuria should be greater and, thus, more
readily detectable in patients with a high fungal burden such as in
AIDS patients with PDH (sensitivity∼90%) than in other patients
(e.g., pulmonary forms, sensitivity ∼75%; Kauffman, 2008). This
observation corroborates the ﬁndings from TB studies when uri-
nary lipoarabinomannan (LAM) was detected more readily from
AIDS patients than from others. Similarly to pneumococcal anti-
gen detection methods, ultraﬁltration of urine was suggested to
improve sensitivity (Srinivasan et al., 2009). As expected, due to
structural similarities of polysaccharides from other dimorphic
fungi (Blastomyces dermatitidis, Coccidioides immitis, Paracoccid-
ioides brasiliensis, and Penicillium marneffei) some interference
from cross-reactivity has been documented (Kauffman, 2008).
OTHER URINARY TESTS FOR DISSEMINATED MYCOSES
In invasive aspergillosis chest x-ray, computer tomography, cul-
ture, and microscopy may not always lead to diagnosis. The
commercial Platelia™Aspergillus ELISA detects galactomannan
from Aspergillus spp. The method was tested with 105 samples
from hematological patients using sera, urine, or bronchoalveolar
lavage. Serum and urine analyses were positive in 14 and 5% of
samples, respectively. Ten-fold concentration of urine increased
the number of positive samples to 8%. In six patients with con-
ﬁrmed invasive aspergillosis the antigen was detected in serum,
but only in two was the urine test positive, suggesting serum is a
preferred sample for screening (Salonen et al., 2000).
A urine test to detect B. dermatitidis antigen (Durkin et al.,
2004) has a sensitivity of 92% (in pulmonary and in disseminated
forms and good speciﬁcity in healthy volunteers but interference
from cross-reactivity occurred in 96.3% of patients with histo-
plasmosis, 100% in paracoccidioidomycosis, 70% in penicilliosis,
and very low cross-reactivity in patients with cryptococcosis and
aspergillosis (Durkin et al., 2004).
Another capture-based EIA detects antigens from C. immi-
tis (Durkin et al., 2009). This test was applied both to serum
and urine. The authors claimed that they were able to measure
galactomannan from urine samples at concentrations down to
0.07 ng/ml yielding clinical sensitivity of 50%.
In summary, results of tests for fungal antigenuria are promis-
ing. However, the clinical relevance of some methods is difﬁcult to
reproduce by outside laboratories because they are proprietary to
the companies (Scheel et al., 2009).
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES IN URINE
Despite availability of pneumococcal vaccines, Streptococcus pneu-
moniae is the number one causative agent of community acquired
pneumonia (CAP), sepsis, and meningitis. The diagnostic utility
of excreted soluble urine antigen in patients with pneumonia was
ﬁrst described in 1917 (Dochez and Avery, 1917). Current diag-
nostic aids have been recently reviewed (Klugman et al., 2008).
According to the authors the sensitivity of all methods to iden-
tify S. pneumoniae in CAP remains inadequate. Bacterial isolation
from patients with pneumococcal CAP was successful from less
than 20% (Klugman et al., 2008) to 37.5% (Marcos et al., 2003).
Urinary diagnostics can be a useful adjunct to culture. A positive
result is highly indicative of S. pneumoniae as the causative agent in
adults but less so in infants due to microbial colonization in their
nasopharyngeal cavity (Klugman et al., 2008). The urinary test is
basedon thedetectionof polysaccharideCcommon in all clinically
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signiﬁcant serogroups. For example, immunochromatographic
membrane assay (ICT) Binax® NOW S. pneumonia Urinary Anti-
gen Test (ME, USA) using blood culture as the gold standard for
positives displayed a sensitivity of 86–90% and speciﬁcity 71–94%,
the latter being dependent on the study cohort. In a large study
(Marcos et al., 2003) the sensitivity reached 100% in patients with
deﬁnitive pneumococcal pneumonias and 69.2% in patients with
probable pneumonia, whereas in patients without pneumococ-
cal pneumonia a false positive rate of 18% was observed. These
authors further advocated the use of concentrated urine; however,
they did not clearly address the issue of speciﬁcity. The Binax®
NOW provides qualitative antigen identiﬁcation and analytical
sensitivity is expressed in terms of colony forming units/ml which
is not relevant to the quantities of excreted antigen in terms of
concentration. Concerning speciﬁcity, the manufacturer reported
that urine from patients with UTI displayed variable interfer-
ence (9%) resulting in invalid result interpretations. Interestingly,
urine collected from persons without signs of UTI may also occa-
sionally test false positive although culture negative. The reason
for this interference is presently obscure. One possibility is that
the cross-reactivity is produced by thus far uncharacterized host
inﬂammatory reaction compounds or alimentary components,
rather than bacterial constituents.
The issue of urine concentration remains highly controver-
sial. The manufacturer recommends the use of non-concentrated
urine, but some researchers (Domínguez et al., 2001; Marcos et al.,
2003) claimed that a 25-fold urine concentration may provide
increased sensitivity. In a large prospective evaluation (Marcos
et al., 2003) concentrated urine resulted in a 1.4-fold increase
in positives detected (from 38 to 53%). However, large prospec-
tive evaluation (Murdoch et al., 2001) using concentrated urine
increased positive detection only marginally (from 29 to 30%) in
CAP patients.
Based on ultraﬁltration experiments the size of the C poly-
saccharide of approximately 20–30 kDa was suggested (Murdoch
et al., 2001). Pioneering work performed at The Rockefeller Insti-
tute (NY,USA) in the early 1960s (Gotschlich and Liu, 1967) char-
acterized the polysaccharide C extracted from bacterial culture.
Later, (Sørensen et al., 1990; Karlsson et al., 1999) the polysac-
charide C was studied in details. Still unresolved is the size and
the chemical composition of the antigen that is excreted into the
urine.
LEGIONELLA PNEUMOPHILA POLYSACCHARIDES IN URINE
Suspicion of nosocomial or community acquired legionellosis
warrants immediate diagnosis and differentiation from other
pathogens because the infection requires antibiotic treatment
different from that used in pneumococcal infection.
There are several commercial urinary antigen detection tests
on the market, the majority being developed for the clinically
most important Legionella pneumophila serogroup 1. For example,
Binax® Now Legionella Urinary Antigen Test (Inverness Medical)
is a ICT with a low interference (5%) in cohorts of bacterial pneu-
monia, sepsis, andUTI.When the three ICT antigen detection tests
were compared using 39 unfrozen and non-concentrated urine
samples from patients with Legionnaire’s disease, the sensitivities
were 74.3, 61.5, and 41% for the Binax® Now, the SAS™Legionella
Test (SA Scientiﬁc Inc.) and the Uni-Gold™Legionella Urinary
AntigenPlus (Trinity Biotech;Muñoz et al., 2009).However, recent
comparison of the Binax® NOW ICT to two EIA methods resulted
in superior EIA performance. This retrospective study was per-
formed on 178 frozen urine samples. The authors found that with
non-concentrated urine samples the sensitivity levels of 71.3% for
the Bartels Legionella UrinaryAntigen (Trinity Biotech); 65.1% for
Biotest Legionella Urine Antigen EIA (now marketed by BioRad)
and 37% for Binax® NOW. After concentration, however, signif-
icant differences in sensitivity no longer existed (Guerrero et al.,
2004). The speciﬁcity issues of concentrated vs. non-concentrated
samples are presently unrecognized.
A systematic review and meta-analysis assessed the perfor-
mance of EIA-based and ICT urine antigen detection methods
(Shimada et al., 2009). The authors concluded (Shimada et al.,
2009) that higher quality studies had lower sensitivity, and a publi-
cation bias was evident. In their summary the pooled sensitivity of
urinary methods to detect infection with L. pneumophila, serotype
1 was 74% (95% CI, 68–81%), and the speciﬁcity was 99.1% (95%
CI, 98.4–99.7%).
As a matter of fact, the origin of the test antigen is not reported
in commercial protocols; however, from its strict serogroup speci-
ﬁcity one may assume that it is lipopolysaccharide (LPS), a heat-
stable antigen present in all Gram-negative bacteria. Chemical
analysis of Legionella LPS was performed decades ago (Conlan
and Ashworth, 1986), but the size and the chemical composition
of the excreted polysaccharide are not yet known.
LAM FROM URINE TO ASSIST DIAGNOSIS OF TUBERCULOSIS
Tuberculosis is a global health emergency of enormous propor-
tions. The major obstacles to TB control is the lack of fast,
affordable, and accurate diagnostic techniques both for pulmonary
and extrapulmonary TB in adults and children (Peter et al., 2010;
Yasinskaya et al., 2011). One approach is to detect the presence of
urinary microbial metabolites, e.g., LAM.
Lipoarabinomannan is a structural heat-stable cell-wall gly-
colipid of Mycobacterium tuberculosis. It constitutes up to 15%
of the total bacterial weight. LAM is a virulence factor and is
released from metabolically active or degrading M. tuberculosis
in TB infection. The size of this polymeric structure is variable,
being on the average 17.5 kDa (range 6–34; Chatterjee, 1997; Bren-
nan, 2003; Nigou et al., 2003). The ﬁrst detection of urinary LAM
was described a decade ago (Hamasur et al., 2001). An earlier com-
mercial method (Chemogen Inc., Portland,ME,USA), is presently
marketed as the Clearview™TBELISA (InvernessMedical Innova-
tions). A meta-analysis and systemic review of the diagnosis of TB
using this reagent reported estimates of sensitivity and speciﬁcity
in microbiologically conﬁrmed cases (seven studies) of 13–93 and
87–99%, respectively (Minion et al., 2011). In ﬁve studies with
results stratiﬁed by HIV status, the sensitivity was 3–53% but in
HIV +ve subgroups it was systematically higher and the highest
sensitivity was observed in advanced immunosuppression. In a
large prospective evaluation including 141 patients with deﬁnitive
TB and 172 patients with no proven TB, urine LAM test was pos-
itive in only 17/141 and 1/172, respectively (Dheda et al., 2010).
In this study the sensitivity in HIV +ve patients was 21% and in
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those whose CD4+ cell counts were below 200 cell/mm3 the sen-
sitivity reached 37%; the speciﬁcity being 95–100% (Dheda et al.,
2010). Reported data have shown that better diagnostic utility is
associated with advanced stages of HIV infection and low CD4+
cell count (Dheda et al., 2010). This observation is explained by
an assumption that in TB with AIDS as co-morbidity, bacterial
burden is higher compared to cases without AIDS. Amazingly,
extensive clinical evaluations (Minion et al., 2011) have been per-
formedusing theClearview™TBELISAwithout conﬁrmation that
LAM is, in fact, excreted in urine of TB patients. No evidence is
apparent also for LAM as the analyte detected by the polyclonal
antibodies is the LAM indeed.As in the S. pneumoniae urine detec-
tionmethod cross-reactivitywithpossibly structurally non-related
substances is observed. This ﬁnding may further lead to specula-
tion that mechanisms of assay interference could be common for
assays of this type where polyclonal antibodies are used.
URINE AS A SAMPLE TO STUDY VIRAL INFECTIONS
Human polyomaviruses (HPyVs) are widespread and unique to
humans. High quantities of viral particles can be shed in urine
from a healthy individual. In nephropathy, e.g., after kidney trans-
plantation, in profound immunosuppression or in AIDS, in hem-
orrhagic cystitis (BKV), or in symptoms of central nervous system
compatible with progressive multifocal leucomyelopathy (JCV),
these viruses may no longer be “innocent bystanders” (Kumar,
2010). NAATs for both urine and blood have been developed to
detect, subtype, and estimate viral loads.
Congenital cytomegalovirus (CMV) infection, a leading cause
of sensorineural hearing loss and neurological impairment (Can-
non et al., 2011), can be robustly detected directly from urine.
In primary infections CMV is excreted and can be cultured from
urine for several weeks.
Urine has been utilized as sample for the early diagnosis of
Dengue virus infection. In some situations urine NAATs provided
greater sensitivity thandoes analysis of plasma (Poloni et al., 2010).
Virus-speciﬁc IgG or IgA-class antibodies as serological markers
of this disease have been also detected in urine (Vazquez et al.,
2007).
URINE AS A SAMPLE TO DIAGNOSE SEXUALLY
TRANSMITTED DISEASES
Urine is extremely useful to diagnose infections of the repro-
ductive tract. The recent systematic review (Cook et al., 2005)
on non-invasive testing for Chlamydia trachomatis and Neisseria
gonorrhoeae showed that both assays reached speciﬁcities of 97%
for both infections and in both sexes. However, for chlamydial
infection the pooled sensitivities were: 83.3, 92.5, and 79.9% for
PCR, transcription-mediated ampliﬁcation and strand displace-
ment ampliﬁcation assays in women and 84, 87.7, and 93.1% in
men, respectively. For the gonococcal infection the respective sen-
sitivities in women were 55.6, 91.3, and 84.9%. Therefore, PCR
for gonococcal infection in women performed from urine was not
recommended (Cook et al., 2005).
The newly developed triple assay for the simultaneous detec-
tion of C. trachomatis,N. gonorrhoeae, and Mycoplasma genitalium
(Dx CT/NG/MG assay BioRad, USA) may provide more evidence
about the role of M. genitalium in sexually transmitted diseases
(STDs). This smallest human bacterium has been earlier asso-
ciated with non-gonococcal urethritis in men but now also in
low-risk women. M. genitalium is considered a cause of urethri-
tis,mucopurulent cervicitis, and upper genital tract infections like
pelvic inﬂammatory disease and even infertility (McGowin and
Anderson-Smits, 2011; Weinstein and Stiles, 2011).
EMERGING TECHNOLOGIES AND PATHOGENS
Flow cytometry-based analysis (FACS) that quantiﬁes both bacte-
ria and white blood cells in the urine has emerged as a promising
diagnostic tool (Jolkkonen et al., 2010). Gas chromatography/mass
spectrometry to detect volatile organic components in human
urine has been recently described although not yet implemented in
clinical practice (Banday et al., 2011). Detection of microbial tran-
srenal DNA is an attractive option to diagnose infections (Green
et al., 2009). The authors, however, cited concerns about lack of
standardization of methodology both for pre- and analytical steps,
storage, and transportation of the sample. A nested PCR from
urine and saliva to detected trace amounts of Plasmodium DNA
has been described (Putaporntip et al., 2011). The sensitivity of the
urine method was two to fourfold less than that shown for saliva,
but the combination of both biological ﬂuids displayed a sensi-
tivity superior to that of microscopy. Moreover, double malarial
infections could be easily detected.
As new detection technologies emerge, knowledge about new
pathogens continues to increase. For example, Actinobaculum
schaalii may cause undiagnosed cystitis predominantly in the
elderly and in those persons in whom the primary focus appears
to be anomalies in the genitourinary tract (e.g., benign prostatic
hyperplasia). Most recently it has been associated with blood-
stream infections (Beguelin et al., 2011). Urine FACS may prove
useful to identify less known or unknown pathogens which can
be suspected on the basis of discrepancy between conventional
culture and a positive ﬂuorescence signal denoting “presence” of
bacteria.
CONCLUSION
In the future urine, because of ease of collection, processing, and
storage,may be extensively used for targeted multiplexed analyses.
Current state-of-the-art, however, indicates that some detection
methods still require further understanding of molecular forms
and structures detected, as well as the excretion kinetics of these
polymeric compounds.
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